Gan & Lee Pharmaceuticals (603087.SH): GLR2037 tablets have obtained the Notice of Approval for Clinical Trial of Drugs.
Ganli Pharmaceuticals (603087.SH) announced that the company recently received the "Drug Clinical Trial Approval Notification" for the investigational drug GLR2037 tablets issued by the National Medical Products Administration. The acceptance numbers are CXHL2600098 and CXHL2600099, and the notification numbers are 2026LP00526 and 2026LP00527.
Gan & Lee Pharmaceuticals (603087.SH) announced that the company recently received the Drug Clinical Trial Approval Notice for the investigational drug GLR2037 tablets issued by the National Medical Products Administration. The acceptance numbers are CXHL2600098 and CXHL2600099, and the notice numbers are 2026LP00526 and 2026LP00527.
GLR2037 tablets are a type 1 chemical new drug developed by Gan & Lee Pharmaceuticals, known as a protein degrading targeted chimeric agent (ARPROTAC), intended for the treatment of advanced prostate cancer. Currently, there are no approved PROTAC products on the market globally.
Related Articles
.png)
INFINITY DEV(00640): Shen Kailian resigns as CFO.
SILKWAVE INC (00471): Oversubscription rate of 4.68% for the rights issue.
Goldwind Science & Technology (02208): As of the end of February, a total of 10,000 H shares have been repurchased.
INFINITY DEV(00640): Shen Kailian resigns as CFO.
SILKWAVE INC (00471): Oversubscription rate of 4.68% for the rights issue.
Goldwind Science & Technology (02208): As of the end of February, a total of 10,000 H shares have been repurchased.
RECOMMEND
